PRESS RELEASE published on 05/08/2024 at 20:40, 4 months 10 days ago enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update enVVeno Medical Corporation reported ending the quarter with $42.9 million cash and investments to fund operations through 2025, presenting positive data at the 46th Annual Charing Cross Symposium Financial Results EnVVeno Medical Corporation SAVVE Trial Venous Disease VenoValve FDA Approval
BRIEF published on 04/24/2024 at 12:20, 4 months 25 days ago Significant Clinical Improvements Reported in enVVeno Medical's VenoValve Pivotal Trial FDA Approval Clinical Trial VenoValve Charing Cross Symposium Venous Disease
BRIEF published on 04/24/2024 at 12:20, 4 months 25 days ago Améliorations cliniques significatives signalées dans l'essai pivot VenoValve d'enVVeno Medical VenoValve Essai Clinique Approbation De La FDA Symposium De Charing Cross Maladie Veineuse
PRESS RELEASE published on 04/24/2024 at 12:15, 4 months 25 days ago Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium enVVeno Medical presents positive efficacy data on VenoValve from SAVVE U.S. pivotal trial at Charing Cross International Symposium, showing clinical improvement for severe CVI patients FDA Approval VenoValve SAVVE Trial CVI Patients Venous Disease
BRIEF published on 04/16/2024 at 15:05, 5 months 3 days ago EnVVeno Medical to Present New VenoValve Efficacy Data at Charing Cross Symposium Clinical Trials EnVVeno Medical VenoValve Chronic Venous Insufficiency Charing Cross Symposium
BRIEF published on 04/16/2024 at 15:05, 5 months 3 days ago EnVVeno Medical présentera de nouvelles données sur l'efficacité de VenoValve au symposium de Charing Cross Essais Cliniques EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Symposium De Charing Cross
PRESS RELEASE published on 04/16/2024 at 15:00, 5 months 3 days ago New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRIEF published on 04/09/2024 at 14:50, 5 months 10 days ago EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve® EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
BRIEF published on 04/09/2024 at 14:50, 5 months 10 days ago EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
PRESS RELEASE published on 04/09/2024 at 14:45, 5 months 10 days ago enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024 FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
Published on 09/19/2024 at 17:30, 1 hour 13 minutes ago Airborne Geophysical Survey Completed at Pine Channel Gold Project, Saskatchewan
Published on 09/19/2024 at 17:00, 1 hour 43 minutes ago Cypress Creek Consulting Advises Charter Communications on Inaugural Securitization Financing Facility
Published on 09/19/2024 at 15:45, 2 hours 58 minutes ago eLearners Make eLearning a Daily or Weekly Habit, Voices' eLearning Report Finds
Published on 09/19/2024 at 15:20, 3 hours 23 minutes ago Taurus secures "Best Digital Assets Solution" at 2024 Global BankTech Awards
Published on 09/19/2024 at 15:01, 3 hours 42 minutes ago ful. CashPay: Revolutionizing Healthcare Access for Employers With Uninsured Team Members
Published on 09/19/2024 at 17:52, 50 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 50 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:52, 51 minutes ago EQS-Adhoc: SMT Scharf AG: New CEO joins the Managing Board
Published on 09/19/2024 at 17:45, 58 minutes ago AFG Holding SA acquiert une participation majoritaire dans le groupe allemand Access Holding et prend ainsi le contrôle de
Published on 09/19/2024 at 17:45, 58 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 58 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 58 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)